Treatment of patients with hepatitis C and normal serum aminotransferase levels.
about
Pathological evolution of hepatitis C virus-“Healthy carriers”Hepatitis C: a clinical reviewHigh prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patientsAlanine aminotransferase isoenzymes: molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity.Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity.Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated.Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase LevelsTherapeutic modalities in hepatitis C: challenges and development.Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.Treating viral hepatitis C: efficacy, side effects, and complications.A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT.Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection.Hepatitis C virus load in parenchyma cells correlates with hepatic injury in infected patients.The Rate of Referral of Hepatitis Virus Carriers to Hepatologists and the Factors Contributing to Referral.Is liver biopsy mandatory in children with chronic hepatitis C?Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts.Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases.[Oral enzyme therapy for chronic hepatitis C--a retrospective analysis].A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.Diagnosis and treatment of hepatitis C.The management of chronic viral hepatitis: A Canadian consensus conference 2004.
P2860
Q27489097-483C473D-C963-4466-9595-0CA40C12E3BFQ27490788-02936988-7F1D-47BA-8BE2-7BB5CDC03356Q28481558-CC19725D-95CA-40DA-8F80-69179E57A3D9Q34048452-1DA1B175-3030-4FFD-BEED-B05AED2AE129Q34166233-C704218F-201B-4575-8D1F-98D90716572BQ35182682-D9480C3C-44CD-421F-A139-EAE18E396BEAQ35596078-5858C835-8880-4E03-ACAC-7E4C6C7A6196Q35794315-9F2D531C-2E57-4C69-AD03-470D1C38A854Q35954220-DF839C0A-B5C1-4229-8A1A-F056B7E5CD4FQ36011951-CF6F6FFF-93D9-4C1F-88CB-567C937F164AQ36372611-24EEA986-C765-4372-B738-8D8479CF9ABDQ36564615-3B0FAB5F-1391-47B3-BFA8-4B6D849E6DB5Q37135640-FAB1ADBF-EDE3-4F72-9A25-879BAE28FD60Q37300367-C4732BDE-95B8-4F1C-9C0E-59763ACAD2A3Q37594128-55B1F74B-7151-4454-BB64-443B3E393CBDQ40097439-EF5EFD47-FA18-432C-842C-D90AE67CEADAQ42909398-8D5A0242-21E5-4FAC-AB1F-9D4F72C3574EQ42978398-7EFA1D5A-6677-46A3-ABFC-5708F1CBC57AQ42990208-6AE067F4-3F65-4C61-B123-1C1C15F7773DQ42999127-9F13941A-C1F1-49AB-A3B2-26182FAF1D87Q43707240-22063DB0-734A-4093-92FD-7DEC95D10DCCQ44097379-E7897E98-B36B-47D7-9748-7E98A26B8007Q45031709-5B18B2F5-B422-4856-9E3C-8AECDE020D51Q45399020-470D6EDF-F46E-46CC-85AA-00816C034EE7Q45411339-5113C6C6-9006-410A-86F7-7B824E6BAF44Q46573153-CEBF510D-D442-473E-8D11-0E594FD0AE74Q50574814-3C40C026-FA74-42E8-A987-8627ADE54F53Q50883674-49D090D7-B1A8-47E4-BB4A-B97CC5C6C2F4Q55428306-0CB160F2-B579-4F1A-BE41-BC103B9C42BC
P2860
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@ast
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@en
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@nl
type
label
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@ast
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@en
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@nl
prefLabel
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@ast
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@en
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@nl
P2860
P356
P1433
P1476
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
@en
P2093
Bruce R Bacon
P2860
P304
P356
10.1053/JHEP.2002.36386
P407
P433
P577
2002-11-01T00:00:00Z